Halozyme Therapeutics, Inc. (HALO)Healthcare | Biotechnology | San Diego, United States | NasdaqGS
109.62 USD
-1.46
(-1.314%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
After hours: 109.62 |
Hot Take ↕ | Oct. 10, 2026, 9:29 a.m. EDT
Halozyme presents a compelling growth story with revenue expanding nearly 48% and earnings surging 43%, supported by robust gross margins above 76%. The stock is trading near its 52-week high, comfortably above its 200-day moving average, indicating strong technical momentum. While the analyst consensus has recently lowered price targets, implying a potential correction, the underlying business quality remains exceptional with a forward P/E of just 10x. The primary headwind is the balance sheet, which carries significant leverage relative to equity, preventing a top-tier long-term rating despite the superior growth profile. There is no income component for investors. Options flow confirms a bullish bias for the long term, with speculators buying calls far out the money. For a swing trader, the momentum is favorable, but the high debt load warrants caution for a permanent holder seeking a fortress balance sheet. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.129743 |
| AutoETS | 0.251034 |
| AutoTheta | 0.251078 |
| MSTL | 0.251373 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 44% |
| H-stat | 0.30 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.215 |
| Excess Kurtosis | -0.61 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1517.687 |
| Revenue per Share | 14.153 |
| Market Cap | 12,441,651,200 |
| Trailing P/E | 32.05 |
| Forward P/E | 10.31 |
| Beta | 0.88 |
| Profit Margins | 24.86% |
| Website | https://halozyme.com |
As of Oct. 10, 2026, 9:29 a.m. EDT: Speculators are positioning for long-term upside, evidenced by heavy out-of-the-money call open interest on December 2027 expirations compared to puts. Shorter-dated options show mixed sentiment with elevated implied volatility at the money, suggesting uncertainty around current levels, but the overall open interest skew favors bullish outcomes over the next year.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.6666167 |
| Address1 | 12,390 El Camino Real |
| All Time High | 116.85 |
| All Time Low | 1.41 |
| Ask | 116.28 |
| Ask Size | 1 |
| Audit Risk | 3 |
| Average Analyst Rating | 1.7 - Buy |
| Average Daily Volume10 Day | 2,312,820 |
| Average Daily Volume3 Month | 2,183,487 |
| Average Volume | 2,183,487 |
| Average Volume10Days | 2,312,820 |
| Beta | 0.877 |
| Bid | 104.89 |
| Bid Size | 1 |
| Board Risk | 1 |
| Book Value | 1.259 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 4 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 109.62 |
| Current Ratio | 2.709 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 111.92 |
| Day Low | 108.81 |
| Debt To Equity | 1,517.687 |
| Display Name | Halozyme Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,048,200 |
| Earnings Call Timestamp Start | 1,786,048,200 |
| Earnings Growth | 0.429 |
| Earnings Quarterly Growth | 0.392 |
| Earnings Timestamp | 1,786,046,400 |
| Earnings Timestamp End | 1,793,649,600 |
| Earnings Timestamp Start | 1,793,649,600 |
| Ebitda | 1,050,688,000 |
| Ebitda Margins | 0.63152003 |
| Enterprise To Ebitda | 13.853 |
| Enterprise To Revenue | 8.748 |
| Enterprise Value | 14,554,888,192 |
| Eps Current Year | 8.71401 |
| Eps Forward | 10.6326 |
| Eps Trailing Twelve Months | 3.42 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 858 704 8311 |
| Fifty Day Average | 106.217 |
| Fifty Day Average Change | 3.4029999 |
| Fifty Day Average Change Percent | 0.032038186 |
| Fifty Two Week Change Percent | 66.66167 |
| Fifty Two Week High | 116.85 |
| Fifty Two Week High Change | -7.2299957 |
| Fifty Two Week High Change Percent | -0.061874162 |
| Fifty Two Week Low | 61.23 |
| Fifty Two Week Low Change | 48.390003 |
| Fifty Two Week Low Change Percent | 0.79029894 |
| Fifty Two Week Range | 61.23 - 116.85 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,079,447,400,000 |
| Float Shares | 112,189,368 |
| Forward Eps | 10.6326 |
| Forward P E | 10.309802 |
| Free Cashflow | 337,308,640 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 423 |
| Fullday Change | -1.4599991 |
| Fullday Change Percent | -1.3143672 |
| Fullday Price | 109.62 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.76271003 |
| Gross Profits | 1,268,945,024 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.010829999 |
| Held Percent Institutions | 1.13185 |
| Implied Shares Outstanding | 113,498,000 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California. |
| Long Name | Halozyme Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 12,441,651,200 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_7931206 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 413,596,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 12,761,715,120 |
| Number Of Analyst Opinions | 9 |
| Open | 111.92 |
| Operating Cashflow | 818,595,008 |
| Operating Margins | 0.59803003 |
| Overall Risk | 2 |
| Payout Ratio | 0.0 |
| Phone | 858 794 8889 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 109.62 |
| Post Market Time | 1,791,921,625 |
| Previous Close | 111.08 |
| Price Eps Current Year | 12.579742 |
| Price Hint | 2 |
| Price To Book | 87.06911 |
| Price To Sales Trailing12 Months | 7.4781313 |
| Profit Margins | 0.24858999 |
| Quick Ratio | 1.994 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.66667 |
| Region | US |
| Regular Market Change | -1.4599991 |
| Regular Market Change Percent | -1.3143672 |
| Regular Market Day High | 111.92 |
| Regular Market Day Low | 108.81 |
| Regular Market Day Range | 108.81 - 111.92 |
| Regular Market Open | 111.92 |
| Regular Market Previous Close | 111.08 |
| Regular Market Price | 109.62 |
| Regular Market Time | 1,791,921,601 |
| Regular Market Volume | 1,772,623 |
| Return On Assets | 0.25492 |
| Return On Equity | 1.73674 |
| Revenue Growth | 0.477 |
| Revenue Per Share | 14.153 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 113,498,000 |
| Shares Percent Shares Out | 0.1348 |
| Shares Short | 15,295,841 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 14,880,707 |
| Short Name | Halozyme Therapeutics, Inc. |
| Short Percent Of Float | 0.1767 |
| Short Ratio | 6.48 |
| Source Interval | 15 |
| State | CA |
| Symbol | HALO |
| Target High Price | 130.0 |
| Target Low Price | 78.0 |
| Target Mean Price | 104.88889 |
| Target Median Price | 105.0 |
| Total Cash | 231,003,008 |
| Total Cash Per Share | 2.035 |
| Total Debt | 2,178,533,120 |
| Total Revenue | 1,663,737,984 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 3.42 |
| Trailing P E | 32.05263 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 79.63255 |
| Two Hundred Day Average Change | 29.98745 |
| Two Hundred Day Average Change Percent | 0.37657276 |
| Type Disp | Equity |
| Volume | 1,772,623 |
| Website | https://halozyme.com |
| Zip | 92,130 |